ALLMedicine™ Waldenstrom Macroglobulinemia Center

May 8th, 2022 - Waldenstrom macroglobulinemia and simultaneous intravascular large B-cell lymphoma: Rare transformation or unhappy coincidence?|2022|Kline KAF,Lee ST,Law JY,Kallen M,|

May 6th, 2022 - B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell l...

Apr 27th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of pomalidomide in patients with relapsed or refractory Waldenstrom macroglobulinemia. SECONDARY OBJECTIVES: I. To evaluate the safety and toxicity profile of pomalidomide in pat...

Apr 12th, 2022 - The development of Bruton tyrosine kinase (BTK) inhibitors has significantly changed the treatment landscape for patients with Waldenström macroglobulinemia (WM). Ibrutinib was the first BTK inhibitor to receive FDA approval for this disease, but ...

Mar 26th, 2022 - Small B-cell lymphoma is the classification of B-cell chronic lymphoproliferative disorders that include chronic lymphocytic leukaemia/small lymphocytic lymphoma, follicular lymphoma, mantle cell lymphoma, marginal zone lymphoma, lymphoplasmacytic...

May 6th, 2022 - B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell l...

Apr 27th, 2022 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of pomalidomide in patients with relapsed or refractory Waldenstrom macroglobulinemia. SECONDARY OBJECTIVES: I. To evaluate the safety and toxicity profile of pomalidomide in pat...

Mar 17th, 2022 - Participants will be asked to complete a medical survey which includes demographics, diagnosis, and treatment history, medical history, lab results and symptoms experienced. Participants will then receive instructions for the tissue banking proced...

Oct 4th, 2021 - PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose (MTD) of temsirolimus in combination with bortezomib, rituximab, dexamethasone in patients with relapsed Waldenstrom's macroglobulinemia and relapsed/refractory mantle cell, follicular...

Aug 9th, 2021 - PRIMARY OBJECTIVE: I. To determine the efficacy (as assessed by complete response [CR] rate) of the combination of ixazomib citrate (ixazomib) and ibrutinib in Waldenstrom macroglobulinemia (WM) patients. SECONDARY OBJECTIVES: I. To assess the ove...

Oct 29th, 2021 - When to initiate treatment is as important as what to use for the treatment of patients newly diagnosed with Waldenstrom macroglobulinemia (WM), a leading expert in the disease emphasizes. "We have to be very careful not to tell patients they have...

Apr 2nd, 2021 - Transcript: Ian W. Flinn, MD, PhD: Let’s talk about BTK [Bruton tyrosine kinase] inhibitors in follicular lymphoma. I think they’re commonly prescribed, more commonly than you would imagine in the relapsed setting in patients with that. That’s...

Apr 2nd, 2021 - Today- An FDA approval in Waldenstrom macroglobulinemia, a priority review in multiple myeloma, a new drug application submitted in myeloma, European approvals of chimeric antigen receptor T-cell therapies, and a US Preventative Task Force scre...

Jan 27th, 2021 - Ibrutinib (Imbruvica) has "become for many clinicians the treatment of choice" for patients with relapsed or refractory Waldenstrom macroglobulinemia (WM). This class of agents (Bruton tyrosine kinase [BTK] inhibitors) represents a "paradigm shift...

Dec 20th, 2020 - Patients with chronic lymphocytic leukemia (CLL) who are being treated with ofatumumab (Arzerra) will soon have to get their therapy through an oncology patient access program, as Novartis, the manufacturer, will no longer be selling the drug comm...